GlassScriptPhysician profile
Frank Kara
NPI 1932504693
$6,596.22
in general payments reported to CMS, 2019-2025
26 companies · $1,676 in 2025
The $1,676 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $723 · 2022: $1,003 · 2023: $1,530 · 2024: $1,665 · 2025: $1,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,859 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,858.62 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,314.95 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $984.12 | 2021-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $689.13 | 2021-2025 | Rexulti, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $555.10 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $505.82 | 2021-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $440.28 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $338.88 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $338.55 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $335.05 | 2021-2025 | Caplyta |
| Alkermes, INC. | $199.63 | 2022-2025 | Aristada, Lybalvi |
| Harmony Biosciences LLC | $139.83 | 2023-2025 | Wakix |
| Sunovion Pharmaceuticals INC. | $100.72 | 2021 | |
| Vanda Pharmaceuticals INC. | $79.72 | 2021-2025 | Fanapt |
| Almatica Pharma LLC | $76.72 | 2021-2023 | Gralise |
| Neos Therapeutics, LP | $71.16 | 2022-2025 | Adzenys Xr-Odt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $69.75 | 2022-2024 | Azstarys |
| Tris Pharma INC | $67.63 | 2022-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $65.49 | 2024-2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $60.64 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $43.10 | 2024 | |
| Noven Therapeutics, LLC | $24.92 | 2024 | Xelstrym, Secuado |
| Jazz Pharmaceuticals INC. | $24.72 | 2022 | |
| Collegium Pharmaceutical, INC. | $22.18 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $19.23 | 2023 | Aplenzin, Wellbutrin |
| Neuronetics, INC. | $15.40 | 2021 | |
| Adlon Therapeutics L.P. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Kara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.